0 NASDAQ Companies - November 9, 2018Immune Design to Present at Jefferies 2018 London Healthcare ConferenceSEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) — Immune Design (Nasdaq: IMDZ), an immunotherapy company focused […]Read More
0 NASDAQ Companies - November 9, 2018Sigma Labs Updates Reporting Dates For Third Quarter 2018 Financial Results and Conference CallCompany to release financial results on Wednesday, November 14, 2016 after market close and host conference call on Friday, November […]Read More
0 NASDAQ Companies - November 9, 2018Motorcar Parts of America to Delay Filing of Fiscal Second Quarter 10-QLOS ANGELES, Nov. 09, 2018 (GLOBE NEWSWIRE) — Motorcar Parts of America, Inc. (Nasdaq: MPAA) today announced the company will […]Read More
0 NASDAQ Companies - November 9, 2018Spring Bank Announces Additional Inarigivir Results at AASLD Conference*Results from full 24 weeks of dosing from the first three cohorts of the ongoing Phase 2 ACHIEVE trial in […]Read More
0 NASDAQ Companies - November 9, 2018Chembio to Participate in Upcoming Investor ConferencesMEDFORD, N.Y., Nov. 09, 2018 (GLOBE NEWSWIRE) — Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care diagnostic tests for […]Read More
0 NASDAQ Companies - November 9, 2018Study on Molecular Templates’ PD-L1 ETB with Antigen Seeding Technology Presented at SITC Annual MeetingAntigen Seeding Technology (AST) is a Potent and Complimentary Addition to Company’s Engineered Toxin Bodies (ETB) Technology AUSTIN, Texas, Nov. […]Read More
0 NASDAQ Companies - November 9, 2018Liquidia Technologies to Present at Jefferies London Healthcare ConferenceRESEARCH TRIANGLE PARK, N.C., Nov. 09, 2018 (GLOBE NEWSWIRE) — Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company […]Read More
0 NASDAQ Companies - November 9, 2018Arsanis Reports Financial Results for Third Quarter 2018WALTHAM, Mass. and VIENNA, Austria, Nov. 09, 2018 (GLOBE NEWSWIRE) — Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused […]Read More
0 NASDAQ Companies - November 9, 2018Scholar Rock Demonstrates that Highly Specific TGFβ1 Inhibition Combined with Anti-PD1 Drives Tumor Regression and Survival Benefit in Preclinical Models of Primary Resistance to Checkpoint Blockade TherapyPreclinical Data Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting Shows Highly Specific Inhibitor of TGFβ1, SRTβ1-Ab3, […]Read More
0 TSX News - November 9, 2018Kelt Reports Financial and Operating Results for the Three and Nine Months Ended September 30, 2018CALGARY, Alberta, Nov. 09, 2018 (GLOBE NEWSWIRE) — Kelt Exploration Ltd. (TSX:KEL) (“Kelt” or the “Company”) has released its financial […]Read More